Atria Investments Inc Cuts Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Atria Investments Inc decreased its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 29.3% in the 3rd quarter, HoldingsChannel reports. The fund owned 15,508 shares of the company’s stock after selling 6,415 shares during the quarter. Atria Investments Inc’s holdings in Takeda Pharmaceutical were worth $221,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC grew its holdings in Takeda Pharmaceutical by 38.6% in the second quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock valued at $43,000 after purchasing an additional 859 shares during the last quarter. Hexagon Capital Partners LLC grew its stake in Takeda Pharmaceutical by 34.3% in the 3rd quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company’s stock valued at $63,000 after acquiring an additional 1,129 shares during the last quarter. Headlands Technologies LLC purchased a new position in Takeda Pharmaceutical during the 2nd quarter valued at about $59,000. Blue Trust Inc. increased its holdings in Takeda Pharmaceutical by 74.0% during the 2nd quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock valued at $76,000 after acquiring an additional 2,330 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in Takeda Pharmaceutical by 136.1% during the third quarter. GAMMA Investing LLC now owns 6,295 shares of the company’s stock worth $90,000 after acquiring an additional 3,629 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Up 0.4 %

Shares of Takeda Pharmaceutical stock opened at $13.38 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.28 and a quick ratio of 0.77. The company has a market capitalization of $42.57 billion, a P/E ratio of 23.07, a P/E/G ratio of 0.25 and a beta of 0.54. Takeda Pharmaceutical Company Limited has a 1 year low of $12.57 and a 1 year high of $15.08. The business has a 50 day moving average price of $14.10 and a 200 day moving average price of $13.84.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.